Sector News

Stryker to spend up to $500M to boost spine unit with imaging, robotics tech

September 5, 2019
Life sciences

Stryker follows a slew of medtechs that have aimed to deepen their robotic surgery capabilities this year through acquisitions: Johnson & Johnson bought out Auris Health for $3.4 billion, Intuitive Surgical added Schölly Fiberoptic’s robotic endoscope business, and Siemens Healthineers last month purchased Corindus Vascular Robotics.

The acquisition is also the third announced by Stryker this year, with the company having previously picked up chronic rhinitis device maker Arrinex and rotator cuff tear tech company OrthoSpace. Canadian hospital sterilization product manufacturer TSO3 also last month said it had agreed to be acquired by Stryker.

The deal announced Wednesday is the second major medtech exit for Mobius CEO and co-founder Eugene Gregerson, who previously co-founded Breakaway Imaging, which sold its O-arm imaging system to Medtronic’s surgical navigation systems business in 2007.

Stryker’s presence in robotics has been mostly centered on its Mako joint replacement platform for total knee, partial knee and total hip procedures, technologies acquired through its $1.65 billion buyout of Mako Surgical in 2013. Stryker said the product line helped drive its recent 9.9% growth in net sales during the second quarter. The expansion into other robotic surgery technologies comes as Zimmer Biomet’s Rosa robotic surgery platform has begun to take share in some of Mako’s specialties.

Neurotechnology and Spine, Stryker’s smallest division, had 7.4% organic growth last quarter. The company made a major investment in the unit last year with the $1.4 billion acquisition of spinal surgery device maker K2M. The strategy of bolstering spine device sales by enhancing spine surgery platforms appears to be working for at least one competitor; Medtronic reported a bump to its spine implant sales in the most recent quarter thanks to adoption of its Mazor robotic surgery platform.

Stryker anticipates the deal will close in the fourth quarter of 2019 and does not expect it to have material impact on full-year net earnings.

By Maria Rachal

Source: MedTechDive

Related News

January 24, 2020

AstraZeneca aims to go carbon free by 2025—and it’ll spend $1B to do it

Life sciences

LinkedIn Twitter FacebookFor a pharma company selling respiratory drugs, climate change would probably mean more patients and increased sales. But AstraZeneca has committed to contributing its fair share to stop […]

January 24, 2020

Big pharma is the ‘winner’ from US-China deal, say lawyers

Life sciences

LinkedIn Twitter FacebookPhase one of the US-China trade deal agreed last week is a major win for pharmaceutical companies, lawyers have told LSIPR. “Pharmaceutical companies are the big winners from […]

January 23, 2020

Amgen wades deeper into Asia with full control of an Astellas Japanese JV

Life sciences

LinkedIn Twitter FacebookSeven years into a strategic alliance in Japan with Astellas Pharma, Amgen is taking on full control of the local business as the Big Biotech bets more on […]